Managing potassium to optimize therapy in heart failure

Name: Managing potassium to optimize therapy in heart failure
Uploaded: 2018-08-28T02:00:00+00:00
Description: Prof. Van der Meer describes the prevalence of hyperkalemia and its effects on the use of RAAS inhibition and discusses some potential novel potassium bind

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025
Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025
AHA 2025 Clinical Insights: Advancing Cardiology Care
Sotagliflozin in HFpEF Without Diabetes: Inside the SOTA-P-CARDIA Trial from AHA 2025
- Juan Badimon, PhD, FAHA
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
Heart Failure
VICTOR Trial Results: Vericiguat Efficacy and Safety Across Baseline Background Therapy in Contemporary Ambulatory Patients With HFrEF
- Justin Ezekowitz, MD, MBBCh, MSc
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
Heart Failure
VICTOR Prespecified Analysis Results: Vericiguat Effects on Mortality in Ambulatory Patients With HFrEF
- Stephen Greene
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
CME/CE
Innovative Approaches to Managing CKM Syndrome and HFmrEF/HFpEF
0.25 credits
- Riccardo Maria Inciardi, MD, PhD
0.25 credits

Managing potassium to optimize therapy in heart failure

Recommended

Title

Share on ReachMD